These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-003992-35 International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ. not-yet-due
Not reported 2005-003464-30 Double blind randomised cross-over trial to assess the value of screening an adult population for hypothyroidism 2009-04-20 due-trials
Ongoing 2005-003562-42 Trial of Adjunctive Vitamin D in Tuberculosis Treatment (AdjuVIT) not-yet-due
Ongoing 2006-000499-33 Effects of Pregabalin on acid-induced oesophageal pain hypersensitivity in male and female healthy adult volunteers, as investigated in a single centre, placebo-controlled, double-blind, randomised, t... not-yet-due
Completed, but no date 2006-001815-30 Prevention Of Endometrial Tumours (POET) bad-data
Not reported 2006-001963-52 GAMEC-SHORT (S) & GAMEC-ANTHRACYCLINE (A) RISK-ADAPTED PROTOCOL FOR RELAPSED GERM CELL TUMOURS (GCT) 2014-01-17 due-trials
Ongoing, reported early 2006-002210-36 A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC) not-yet-due
Ongoing, reported early 2006-003445-17 The probiotic Bifidobacterium breve strain BBG-01 admistered early to preterm infants to prevent infection, necrotising enterocolitis and death. not-yet-due
Not reported 2006-004071-34 A single centre, parallel group, pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling. 2013-01-17 due-trials
Not reported 2006-004160-32 Biological effects of Goal Directed Therapy in surgical patients 2009-01-10 due-trials
Reported results 2006-004511-21 Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] 2012-04-27 due-trials
Ongoing 2006-005704-13 A Phase II Study of Intravenous CNTO328 in Patients with Recurrent Epithelial Ovarian Cancer not-yet-due
Not reported 2006-006652-35 A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosu... 2012-01-18 due-trials
Ongoing, reported early 2007-001826-28 A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after firrst-line chemotherapy in patients with HER1 and/or HER2 over expressing locally advanced or metastatic b... not-yet-due
Ongoing 2007-002743-24 Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic pa... not-yet-due
Completed, report not yet due 2007-004269-16 Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation. 2010-09-27 not-yet-due
Not reported 2008-000256-26 An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neutra... 2014-02-03 due-trials
Ongoing, reported early 2008-002286-32 Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukaemia... not-yet-due
Not reported 2008-004720-24 Effects of an extended period of varenicline use prior to quitting smoking on post-quitting urges to smoke 2010-02-11 due-trials
Ongoing 2008-005708-18 Prevention of metabolic complications of glucocorticoid excess not-yet-due
Ongoing, reported early 2009-009596-35 Optimisation of Peri-operative Cardiovascular Management to Improve Surgical Outcome (Optimise Trial) not-yet-due
Ongoing, reported early 2009-011264-11 A randomized, double blind, placebo controlled, phase II, multi-centre pilot study to investigate the effects of vitamin D2 or D3 supplementation on metabolic parameters in people at risk of type 2 di... not-yet-due
Not reported 2009-015378-36 Effect of anastrozole on arthralgia and the effect of glucosamine sulphate supplementation in postmenopausal women with arthralgia in the IBIS-II breast cancer prevention trial 2010-09-30 due-trials
Ongoing, reported early 2009-015626-11 Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate-5-lipoxygenase (ALOX5) promoter genotype. not-yet-due
Ongoing, reported early 2009-016675-29 A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER] not-yet-due
Ongoing 2010-019874-34 A randomised, placebo controlled, double-blind, cross-over trial of the Polypill on risk factor reduction not-yet-due
Not reported 2010-021277-36 REGENERATE – AMI 2017-09-08 due-trials
Ongoing 2011-000626-29 Keloid Scars: A randomised clinical and laboratory based study on the treatment and differentiation factors of the local disease not-yet-due
Reported results 2011-005565-20 Comparison of the effects of the electronic cigarette and nicotine inhalator on tobacco withdrawal symptoms over 24 hours of abstinence 2013-02-21 due-trials
Ongoing 2012-000326-22 A PHASE I/II DOSE ESCALATION TRIAL OF HDAC INHIBITOR TEFINOSTAT (CHR-2845) FOR CANCER ASSOCIATED INFLAMMATION IN HEPATOCELLULAR CARCINOMA not-yet-due
Reported results 2012-000478-42 NEPTUNE: A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer 2015-06-02 due-trials
Ongoing 2012-001495-11 The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BMMNC) on all causemortality in acute myocardial infarction not-yet-due
Reported results 2012-002874-30 AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY 2014-12-31 due-trials
Reported results 2012-004847-61 A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced... 2015-06-10 due-trials
Ongoing 2013-000893-32 Squamous cell carcinoma prevention in organ transplant recipients using topical treatments: a feasibility study (SPOT) not-yet-due
Ongoing 2013-001521-43 A Phase II, double blind, randomised, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer not-yet-due
Ongoing 2013-002403-34 A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer. not-yet-due
Ongoing 2013-002419-87 Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial not-yet-due
Reported results 2013-003729-27 Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin 2016-11-01 due-trials
Ongoing 2014-000199-25 A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cell l... not-yet-due
Ongoing 2014-001784-13 PROVENT: A randomised, double blind, placebo controlled feasibility study to examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease progression in men on active surveillanc... not-yet-due
Ongoing 2014-002001-37 Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer. not-yet-due
Ongoing 2014-002613-31 A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers. not-yet-due
Ongoing 2014-003529-16 Stratification of Biologic Therapies for RA by Pathobiology (STRAP): A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Toc... not-yet-due
Completed, report not yet due 2014-004430-26 FEASIBILITY of IBIS 3. An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment 2018-03-26 not-yet-due
Ongoing 2015-000301-40 A randomised, blinded, placebo-controlled Phase 2a study to evaluate the safety and efficacy of Artesunate treatment in severely injured trauma patients with traumatic haemorrhage. not-yet-due
Ongoing 2015-001112-35 A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder not-yet-due
Ongoing 2016-000599-87 Response guided therapy with daclatasvir, sofosbuvir and ribavirin for 12 or 24 weeks in patients with genotype 3 chronic hepatitis C virus: is longer therapy worthwhile? not-yet-due
Ongoing 2016-004141-90 Phase III mechanistic, randomised controlled trial of Stopping Perioperative Angiotensin II Converting Enzyme inhibitors and/or receptor blockers in major noncardiac surgery not-yet-due
Ongoing 2016-004424-38 A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer. not-yet-due
Ongoing 2017-004079-30 Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, ... not-yet-due
Ongoing 2018-000977-62 BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer not-yet-due